Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration. / Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela Di; Wallman, Johan K.; Pavelka, Karel; Závada, Jakub; Nissen, Michael J.; Jones, Gareth T.; Relas, Heikki; Pirilä, Laura; Tomšič, Matija; Rotar, Ziga; Geirsson, Arni Jon; Gudbjornsson, Bjorn; Kristianslund, Eirik K.; van sder Horst-Bruinsma, Irene; Loft, Anne Gitte; Laas, Karin; Iannone, Florenzo; Corrado, Addolorata; Ciurea, Adrian; Santos, Maria J.; Santos, Helena; Codreanu, Catalin; Akkoc, Nurullah; Gunduz, Ozgul S.; Glintborg, Bente; Østergaard, Mikkel; Hetland, Merete Lund.
I: Seminars in Arthritis and Rheumatism, Bind 56, 152081, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors
T2 - Data from the EuroSpA collaboration
AU - Ørnbjerg, Lykke M.
AU - Linde, Louise
AU - Georgiadis, Stylianos
AU - Rasmussen, Simon H.
AU - Lindström, Ulf
AU - Askling, Johan
AU - Michelsen, Brigitte
AU - Giuseppe, Daniela Di
AU - Wallman, Johan K.
AU - Pavelka, Karel
AU - Závada, Jakub
AU - Nissen, Michael J.
AU - Jones, Gareth T.
AU - Relas, Heikki
AU - Pirilä, Laura
AU - Tomšič, Matija
AU - Rotar, Ziga
AU - Geirsson, Arni Jon
AU - Gudbjornsson, Bjorn
AU - Kristianslund, Eirik K.
AU - van sder Horst-Bruinsma, Irene
AU - Loft, Anne Gitte
AU - Laas, Karin
AU - Iannone, Florenzo
AU - Corrado, Addolorata
AU - Ciurea, Adrian
AU - Santos, Maria J.
AU - Santos, Helena
AU - Codreanu, Catalin
AU - Akkoc, Nurullah
AU - Gunduz, Ozgul S.
AU - Glintborg, Bente
AU - Østergaard, Mikkel
AU - Hetland, Merete Lund
N1 - Publisher Copyright: © 2022
PY - 2022
Y1 - 2022
N2 - Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.
AB - Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.
KW - Ankylosing spondylitis disease activity score
KW - Axial spondyloarthritis
KW - Predictors
KW - TNF-inhibitors
U2 - 10.1016/j.semarthrit.2022.152081
DO - 10.1016/j.semarthrit.2022.152081
M3 - Journal article
C2 - 35985172
AN - SCOPUS:85135923596
VL - 56
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
SN - 0049-0172
M1 - 152081
ER -
ID: 320651940